Back to Authors

Chanan‐Khan, Asher

https://orcid.org/0000-0002-4702-6772

A5010286156 | I4210146710

Mayo Clinic in Florida

Citations 260

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7237-7238

10.1182/blood-2022-169533

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9904-9905

10.1182/blood-2022-164667

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2326-2328

10.1182/blood-2022-160386

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9470-9472

10.1182/blood-2022-159586

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9331-9332

10.1182/blood-2022-165377

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10165-10166

10.1182/blood-2022-165209

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10017-10019

10.1182/blood-2022-167181

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9363-9365

10.1182/blood-2022-168232

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9242-9243

10.1182/blood-2022-167543

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7050-7052

10.1182/blood-2022-157060